PSNL · Personalis, Inc.
$16.88
+1.07 (+6.77%)
At close · Aug 20
Market Cap
$1.78B
Shares
106.80M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$16.88
Open$15.91
Day$15.91–17.06
52W close$4.64–16.88
Avg vol 30d4.5M
Short int8.7M · 8.2% float · 1.7d
Short vol23%
Last earningsAug 4, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 4
Up next
Next earnings call
Nov 2, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 4, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+80%
above
Price vs 50-day avg
+30%
above
RSI (14)
72
overbought
MACD trend
Positive
52-week position
100%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+38%
trailing
6-month return
+86%
trailing
YTD return
+112%
this year
Relative strength
+75%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $13 › 200d $9 — 50d above 200d
Institutional flow
Accumulating
+10% holders QoQ · +41 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
8.16% of float · ▼ -21.5% MoM · 1.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
157 holders — near 3-yr high, broad support
Squeeze score
60
elevated · 0–100
Fundamentals
Revenue growth
−18%
Y/Y
EPS growth
+34%
Y/Y
Free cash flow
$-79.5M
Balance sheet
$119.2M
net cash
Quant / Vol
risk profile
Volatility
92%
annualized · 1-yr
Max drawdown
−55%
past year
ATR
5.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 7, 2026
Total company revenue
· full year 2026
$78M – $80M
Clinical revenue
· full year 2026
$10M – $11M
Revenue from pharma testing services and all other customers
· full year 2026
$55M – $56M
Revenue from population sequencing and enterprise sales
· full year 2026
$13M
Gross margin
· full year 2026
15% – 20%
Net loss
· full year 2026
$-105M
Cash usage
· full year 2026
$100M
Prior guidance
period ended
· from the 8-K filed Nov 4, 2025
Total company revenue
· fourth quarter of 2025
$15.7M – $20.7M
Revenue from pharma tests and services, and all other customers
· fourth quarter of 2025
$12M – $17M
Revenue from population sequencing and enterprise sales
· fourth quarter of 2025
$3.7M
Total company revenue
· full year of 2025
$68M – $73M
Revenue from pharma tests and services, and all other customers
· full year of 2025
$50M – $54M
Gross margin
· full year of 2025
22% – 24%
Revenue from population sequencing and enterprise sales
· full year of 2025
$16.5M – $17M
Cash usage
· full year of 2025
$75M
Guided vs delivered
· last 3 settled
Total company revenue
fourth quarter of 2025
guided $15.7M – $20.7M
$17.35M
In line
Total company revenue
full year of 2025
guided $68M – $73M
$69.65M
In line
Total company revenue
third quarter of 2025
guided $12M – $14M
$14.5M
Beat +11.5%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+80%
Bullish
Price vs 50-day avg
+30%
Bullish
RSI (14)
72
Bearish
MACD trend
Positive
Bullish
52-week position
100%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $13 › 200d $9 — 50d above 200d
Institutional flow
Accumulating
+10% holders QoQ · +41 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
8.16% of float · ▼ -21.5% MoM · 1.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
157 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $5
Now $17 · 100%
Range high $17
vs 200-day avg +80%
vs 50-day avg +30%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filingsFigures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PSNL
this stock
Personalis, Inc.
|
$1.78B | +112.1% | -17.7% | — | 8.2% |
|
TMO
Thermo Fisher Scientific Inc.
|
$231.21B | +8.3% | +14.5% | 33.6 | 1.3% |
|
DHR
Danaher Corp /De/
|
$147.41B | -5.7% | +8.5% | 37.2 | 1.7% |
|
NTRA
Natera, Inc.
|
$46.86B | +41.8% | -2.8% | — | 3.0% |
|
IDXX
Idexx Laboratories Inc /De
|
$44.29B | -19.3% | +10.4% | 39.5 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PSNL | +17.1% | +38.1% | +86.3% | +33.3% | +112.1% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +19.0% | +34.8% | +75.1% | +31.3% | +100.2% |
Key facts
CIK
1527753
CUSIP
71535D106
13F (30d)
156 filings
153 filers
Visit website
Investor relations